INTRODUCTION
============

After primary therapies, adherence to follow-up examinations and the optimization of thyrotropin (TSH)-suppressive therapy with levothyroxine (LT4), respectively, contribute to ruling out tumor recurrence and improving quality of life. According to recent guidelines, LT4 dosage in thyroid cancer is age-, tumor stage-, and histology-dependent \[[@B1]\]. Therefore, the balance between necessary and unnecessary exogenous hyperthyroxinemia should always be considered in the management of thyroid cancer patients \[[@B2]\].

It is well known that that about 40% of patients taking LT4 for benign \[[@B3]\] or malignant \[[@B4][@B5]\] thyroid pathologies do not have serum TSH in the adequate range, and the risk of iatrogenic hypothyroxinemia and hyperthyroxinemia is always possible \[[@B2][@B4][@B5][@B6]\]. The main causes of inappropriately high TSH levels are low LT4 dosages for body-weight and composition \[[@B7]\], drugs and foods which interfere with LT4 absorption \[[@B5][@B8]\], common gastrointestinal disorders \[[@B8]\], bariatric surgery \[[@B9]\], and pregnancy \[[@B10]\]. Rarer causes of increased TSH that mimic subclinical hypothyroidism are human anti-mouse antibodies that interfere with immunoassay systems \[[@B11]\] and the macro-molecular complex of TSH and anti-TSH immunoglobulin (macro-TSH \[mTSH\]) \[[@B12]\].

Macro-TSH displays a large molecular size on gel filtration chromatography (\>150 kDa), and has been described in several case reports in recent years \[[@B13][@B14][@B15]\]. As in the case of macro-prolactin \[[@B16]\], the bioactivity of mTSH may be low, and mTSH may accumulate in the circulation, causing spurious elevated TSH levels \[[@B13][@B14][@B15][@B16]\]. More recent papers from Hattori et al. \[[@B17][@B18][@B19]\] reported that (1) mTSH exhibited laboratory features similar to those of subclinical hypothyroidism \[[@B17]\]; (2) that there were no commercial TSH immunoassay platforms that do not cross with mTSH \[[@B18]\]; and (3) that mTSH may persist in patients for a long time \[[@B19]\]. According to these authors, the incidence of subclinical hypothyroidism might be overestimated, owing to the presence of mTSH in sera, and screening for mTSH should be performed before hormone replacement therapy is initiated in subclinical hypothyroidism \[[@B17]\].

To our knowledge, studies on mTSH in other cohorts of patients are lacking. Recently, Kadoya et al. \[[@B20]\] reported that an increase in serum mTSH is associated with poor sleep quality in patients with cardiovascular risk factors and, surprisingly, that mTSH is present even in patients with normal TSH levels and is regulated by different mechanisms from those regulating free-TSH. No data are available in patients with a history of thyroid carcinomas, in whom LT4 therapy must be carefully tailored in order to prevent under-treatment or unnecessary over-treatment.

The aim of our single-center study was to evaluate the prevalence of mTSH in a cohort of patients who had undergone thyroidectomy for thyroid cancer and, as a control group, in patients who had undergone surgery for benign thyroid pathology. As stated by Hattori et al. \[[@B17]\] with regard to subclinical hypothyroidism, our main interest was to determine whether, in patients on chronic LT4 therapy, mTSH screening may be justified when higher than expected LT4 dosages are needed in order to achieve the therapeutic target of serum TSH.

METHODS
=======

Outpatients with a history of thyroid cancer (study group) and outpatients with post-surgical thyroidectomy for benign pathology (control group), over 18 years of age, were recruited in 2016 for the study of mTSH during their annual follow-up examination at our Thyroid Cancer Unit. Written informed consent to participate in the study was obtained from all patients. Data from 73 study group patients and 24 control group patients were evaluated. All subjects were on chronic LT4 treatment in order to reach age- and risk-adjusted TSH levels in the study group and to control post-surgical hypothyroidism in the control group. Brand LT4 in various formulations (tablets, soft gel, liquid solution) was taken on waking, in a fasting condition, 30 minutes before breakfast \[[@B5]\]. Some clinical data are reported in [Table 1](#T1){ref-type="table"}. The majority of thyroid cancers were papillary thyroid cancer (85% of total) with a low-risk stage on diagnosis. Total thyroidectomy was the primary treatment in all but five thyroid cancer patients (93%) and in all but three control subjects (88%). Ablative radioiodine therapy was undertaken in 67% of patients with thyroid cancer of follicular origin. At the time of the study, positive thyroid autoantibodies were found in two study group patients and one control group patient. In all but three cases (two medullary thyroid carcinomas; one papillary thyroid carcinoma) calcitonin (Ct) or thyroglobulin (Tg) levels were indicative of cure (96%). Patients who had undergone more conservative treatments were regarded as cured on the basis of more than 5 years\' stability of their clinical and biochemical status.

Clinical examination comprised neck sonography, body weight (b.w.) evaluation, and pharmacological anamnesis. At the time of examination, which was performed between 2:00 PM and 4:00 PM, blood samples for the study were drawn. Free-T4 (fT4) and TSH levels were evaluated by means of electro-chemiluminescence immunoassays. Methods were optimized on an automated analytic platform (Cobas c701, Roche Diagnostics, Mannheim, Germany). Normal ranges are 12.0 to 22.0 pmol/L for fT4 and 0.3 to 4.2 mIU/L for TSH. The functional sensitivity of the TSH assay is 0.03 mIU/L, with intra- and inter-assay coefficients of variation of 3% and 7%, respectively. Tg and anti-Tg antibody (TgAb) were evaluated as previously reported \[[@B5]\]. Serum Ct was assayed by means of chemiluminescence immunoassay (Dia Sorin, Saluggia, Italy); in our laboratory the upper limit of the normal Ct range is 10 ng/L.

Macro-TSH was screened by adding polyethylene glycol (PEG, 25%; 0.2 mL) to serum (0.2 mL) in order to precipitate γ-globulin fractions. The values of TSH in the supernatant and 1:2 diluted sera were used for the analysis. In accordance with the method of Hattori et al. \[[@B17][@B18][@B19]\], the PEG-precipitable TSH (%), which represents the concentration of mTSH, was calculated as follows: (serum TSH--TSH recovered after PEG)/serum TSH×100. Arbitrarily, a PEG-precipitable TSH (%) value ≥80% was considered suggestive of mTSH in serum.

GraphPad version 6.0 software (GraphPad, San Diego, CA, USA) was used for statistical analysis. To compare continuous data, the Mann-Whitney test was used. Percentages were compared by means of Fisher exact test. Correlations were evaluated by means of the Spearman test. Data are reported as mean±standard error of mean (SEM) if not otherwise reported. Significance was set at *P*≤0.05. Data collection and subsequent analysis were performed in compliance with the Helsinki Declaration and approved by the University of Genoa Ethics Committee.

RESULTS
=======

The study and control groups were similar in age and male/female distribution. The length of time since surgery was significantly greater in the study group than in the control group (*P*=0.002). In keeping with the histological diagnosis, the dosage of LT4 therapy was slightly but significantly higher and TSH levels were slightly but significantly lower (*P*=0.005 for both) in the study group than in controls ([Table 1](#T1){ref-type="table"}). No correlation between fT4 and TSH levels was found in either group ([Fig. 1](#F1){ref-type="fig"}). Only few subjects showed inadequate TSH levels for their clinical condition (study group, 12%; control group, 8%). [Fig. 2](#F2){ref-type="fig"} reports the distribution of PEG-precipitable TSH (%) values in both groups. In both groups, mTSH showed a normal distribution, ranging from 0% to 92%. On average, PEG-precipitable TSH was 39.3%±1.9% in the study group and 44.1%±3.9% in the control group (*P*=0.28). According to our arbitrary criteria, mTSH was deemed to be present in one female patient (75 years old) with a history of low-risk papillary thyroid carcinoma, who was on 1.3 µg/kg b.w. of LT4 to maintain TSH at a level of 1.77 mIU/L. This patient had undergone surgery alone 2 years earlier; we increased the dosage of LT4 to 1.5 µg/kg b.w. in order to maintain TSH levels in the 0.55 to 0.69 mIU/L range. In this patient, hypertension was the only other medical complaint. In two control subjects (one 60-year-old female and one 67-year-old male) with mTSH, thyroidectomy had been performed 5 and 2 years earlier for a follicular nodule and for laryngeal cancer, respectively. LT4 was administered at a dosage of 1.3 and 1.4 µg/kg b.w., respectively, and TSH levels were 0.47 and 0.30 mIU/L. The male control had hyperthyroxinemia (fT4, 25.3 pmol/L), while in the female control fT4 was 17.9 pmol/L. In both subjects, anti-hypertensive therapies were ongoing; the male was also taking calcium carbonate, which can interfere with LT4 absorption. In both subjects, a few adjustments to LT4 dosage were made in order to maintain TSH levels in the 0.31 to 0.94 mIU/L to 0.30 to 0.90 mIU/L ranges, respectively. In all subjects with a suspected history of mTSH, laboratory data were negative for rheumatoid arthritis.

Only in the study group was PEG-precipitable TSH (%) found to be negatively (*P*=0.03) correlated with fT4 concentration ([Fig. 3](#F3){ref-type="fig"}). In neither group was any correlation found between PEG-precipitable TSH (%) and age, sex, body mass index, years since thyroidectomy, tumor stage, radioiodine therapy, Tg levels, TgAb status, b.w.-related LT4 dosage, other concomitant drugs or TSH levels.

DISCUSSION
==========

The prevalence of macro-prolactin in patients with hyperprolactinemia ranges about from 10% to 30%, and it has been reported that this variability is dependent on the immunoassay platforms used \[[@B21]\]. The prevalence of mTSH is not well known. Macro-TSH seems to be a heterogeneous entity which can be suspected when normal fT4 levels are associated to elevated TSH levels, and when substances that commonly interfere with TSH assays, including heterophilic antibodies, human anti-mouse/animal antibodies (HAMA) and rheumatoid factors have been excluded \[[@B22]\]. Macro-TSH can also occur in patients with TSH concentrations within reference ranges \[[@B23]\]. To date, the bulk of data on mTSH prevalence have been provided by studies by Hattori et al. \[[@B17][@B18][@B19]\]. On searching for mTSH in 681 sera from patients with subclinical hypothyroidism, and using a cut-off of PEG-precipitable TSH greater than 75%, these authors found a prevalence of mTSH of 1.6% after gel-filtration \[[@B17]\]. Subsequently, in 1901 sera from subclinical hypothyroidism patients, in which the presence of HAMA had been excluded, the prevalence of mTSH decreased to 0.8% \[[@B18]\]. A similar prevalence (0.6%) was reported by Mills et al. \[[@B24]\] in a study conducted on 495 sera with TSH levels above 10 mIU/L.

No data on cohorts of thyroidectomy patients are available. In our study, PEG-precipitable TSH was 39.3%±1.9% in patients who had undergone total thyroidectomy for thyroid cancer and 44.1%±3.9% in similarly treated patients with a final histological diagnosis of benignity. These percentages seem to be somewhat lower than those reported in 681 samples from subjects with a clinical diagnosis of subclinical hypothyroidism (from 21% to 100%; on average, 63%) \[[@B17]\] and in 10 samples from subjects with presumably normal thyroid function (from 58% to 79%) \[[@B15]\]. On the other hand, mTSH distribution seems to be quite normal in our sera, as in the study by Hattori et al. \[[@B17]\]. In our whole group, according to the arbitrary cut-off of ≥80%, the prevalence of mTSH (3.1%) was higher than that reported in subclinical hypothyroidism \[[@B17][@B18][@B24]\]. It is not clear whether this difference is due to the different cohort of patients or to the lack, in our study, of gel-filtration or HAMA examinations. However, the significant negative correlation seen between TSH after PEG-precipitable evaluation and fT4 concentrations in the study group, but not between TSH and fT4 levels before PEG precipitation, indicates that, in some patients, LT4 is not adequately titrated in relation to both elevated free-TSH and fT4. Literature data indicate that there is an increased need for LT4 in post-thyroidectomy patients, and that a wide range of daily LT4 regimens are available \[[@B25][@B26]\]. This increase has been ascribed to the need to replace direct glandular triiodothyronine production, which is no longer available in post-surgical hypothyroid patients. Our data demonstrate that, in assessing the adequacy of LT4 dosage after total thyroidectomy in thyroid cancer patients, the individual balance of fT4 and mTSH must also be considered.

In their review of published case reports, Loh et al. \[[@B15]\] reported that the majority of patients with mTSH were females without symptoms of thyroid disorders, except for one with clinical features of hyperthyroidism. Hattori et al. \[[@B18]\] stated that mTSH is predominant in samples from elderly patients and that autoimmune mechanisms might be involved in the generation of mTSH \[[@B17]\]. On the other hand, some patients with mTSH have anti-Tg, anti-TSH receptors, and anti-thyroperoxidase antibodies \[[@B15]\]. Although our population consisted of middle-aged and elderly patients, no correlation was noted between mTSH and age or TgAb status. Moreover, no correlation was found in the study group between mTSH and disease stage or previous radioiodine therapy. In our opinion, more data are needed in order to attribute mTSH generation to age, sex, or autoimmunity.

It has been suggested the screening for TSH in subclinical hypothyroidism is necessary before LT4 therapy is initiated \[[@B17][@B18]\]. However, this seems routinely impracticable; the same can probably be said in the case of thyroid cancer patients. Moreover, the detection of mTSH must be undertaken in particular conditions in surgical hypothyroid patients (present data), such as in patients with sleep disorders \[[@B20]\].

Our study has several limitations: (1) both the study and control groups comprised few subjects; (2) no other laboratory procedures were performed after PEG-precipitation; (3) TSH was assayed by means of only one analytical platform; and (4) the cut-off of PEG-precipitable TSH was set arbitrarily.

In conclusion, free-TSH levels after PEG precipitation are on average 40% lower than serum TSH levels in hypothyroid subjects with or without a history of thyroid carcinoma. The presence of mTSH seems to be a rare phenomenon in our patients. Patients suspected of having mTSH must be followed up for a long time, owing to the hypothesized long persistence of the immunoglobulin G-TSH complex \[[@B19]\]. In some patients with low PEG-precipitable TSH (%), a reduction in LT4 dosage could be suggested. Moreover, LT4 dosage adjusted to b.w. is the main factor in maintaining TSH in a semi-suppressed or normal range. More serum samples need to be evaluated in order to strike a balance between adequate TSH suppression and the avoidance of unnecessary long-term exogenous hyperthyroxinemia.
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###### Clinical Data of Study and Control Group Subjects

![](enm-32-460-i001)

  Variable                   Study group (*n*=73)   Control group (*n*=24)   *P* value   
  -------------------------- ---------------------- ------------------------ ----------- --
  Age, yr                    61.9±13.9              63.5±11.2                0.551       
  Sex, female/male           57/16 (78.1/21.9)      19/5 (79.2/20.8)         1.000       
  Years after surgery        11.1±1.0               6.0±1.0                  0.002       
  Thyroid cancer histology                                                               
                             PTC                    62 (84.9)                \-          
                             FvPTC                  5 (6.9)                  \-          
                             FTC                    2 (2.7)                  \-          
                             MTC                    4 (5.5)                  \-          
  AJCC stage on diagnosis                                                                
                             Stage 1                55 (75.3)                \-          
                             Stage 2                7 (9.6)                  \-          
                             Stage 3                9 (12.3)                 \-          
                             Stage 4                1 (1.4)                  \-          
                             Unknown                1 (1.4)                  \-          
  Radioiodine ablation       47 (64.4)              \-                                   
  LT4, µg/kg b.w.            1.57±0.04              1.37±0.08                0.005       
  fT4, pmol/L                20.3±0.4               20.5±0.5                 0.869       
  TSH, mIU/L                 1.08±0.16              1.64±0.28                0.005       

Values are expressed as mean±SEM or number (%). Tumor staging was done according to the American Joint Committee on Cancer (AJCC) 7th edition, AJCC.

PTC, papillary thyroid cancer; FvPTC, follicular variant of PTC; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; LT4, levothyroxine; b.w., body weight; fT4, free-T4; TSH, thyrotropin.
